Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adbelizumab with concurrent or sequential radical chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma
ChiCTR2300076371Phase 4Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Oct 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of adebrelimab in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: 12-month progression-free survival rate. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2300076371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076371.